An Open-Label, Multiple-Dose, Randomized, 3-Way Crossover Study In Healthy Volunteers To Determine The Steady-State Pharmacokinetics Of The 82.5 Mg And 165 Mg Dose Strengths Of Pregabalin Controlled Release Formulations Administered Following An Evening Meal And 75 Mg Of The Immediate Release Formulation Administered Twice Daily.

Trial Profile

An Open-Label, Multiple-Dose, Randomized, 3-Way Crossover Study In Healthy Volunteers To Determine The Steady-State Pharmacokinetics Of The 82.5 Mg And 165 Mg Dose Strengths Of Pregabalin Controlled Release Formulations Administered Following An Evening Meal And 75 Mg Of The Immediate Release Formulation Administered Twice Daily.

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Jul 2014

At a glance

  • Drugs Pregabalin (Primary)
  • Indications Epilepsy; Fibromyalgia; Generalised anxiety disorder; Irritable bowel syndrome; Neuropathic pain; Postherpetic neuralgia; Postoperative pain
  • Focus Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 10 Jan 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Jan 2011 Planned end date changed from 1 Dec 2010 to 1 Jan 2011 as reported by ClinicalTrials.gov.
    • 06 Dec 2010 Actual initiation date (Nov 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top